Corcept Therapeutics Incorporated (CORT): Price and Financial Metrics


Corcept Therapeutics Incorporated (CORT)

Today's Latest Price: $17.78 USD

0.08 (0.45%)

Updated Oct 20 4:00pm

Add CORT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

CORT Stock Summary

  • For CORT, its debt to operating expenses ratio is greater than that reported by just 5.24% of US equities we're observing.
  • CORT's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 8.99% of US stocks.
  • With a year-over-year growth in debt of 205.31%, Corcept Therapeutics Inc's debt growth rate surpasses 92.46% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Corcept Therapeutics Inc, a group of peers worth examining would be NPTN, NBIX, FLGT, SEDG, and ANET.
  • Visit CORT's SEC page to see the company's official filings. To visit the company's web site, go to www.corcept.com.

CORT Stock Price Chart Interactive Chart >

Price chart for CORT

CORT Price/Volume Stats

Current price $17.78 52-week high $23.48
Prev. close $17.70 52-week low $9.70
Day low $17.66 Volume 750,700
Day high $18.19 Avg. volume 1,603,966
50-day MA $16.45 Dividend yield N/A
200-day MA $14.43 Market Cap 2.05B

Corcept Therapeutics Incorporated (CORT) Company Bio


Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders. The company was founded in 1998 and is based in Menlo Park, California.

CORT Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$17.78$1008.4 5597%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Corcept Therapeutics Inc. To summarize, we found that Corcept Therapeutics Inc ranked in the 95th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. In terms of the factors that were most noteworthy in this DCF analysis for CORT, they are:

  • The company's balance sheet shows it gets 100% of its capital from equity, and 0% of its capital from debt. Its equity weight surpasses that of 95.31% of free cash flow generating stocks in the Healthcare sector.
  • The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately merely 2.31% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • Corcept Therapeutics Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -26.74. This coverage rate is greater than that of merely 4.54% of stocks we're observing for the purpose of forecasting via discounted cash flows.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%5485%
1%5541%
2%5597%
3%5653%
4%5709%
5%5765%

Want more companies with a valuation profile/forecast similar to that of Corcept Therapeutics Inc? See BEAT, USNU, AMRX, ACHC, and AMEH.


CORT Latest News Stream


Event/Time News Detail
Loading, please wait...

CORT Latest Social Stream


Loading social stream, please wait...

View Full CORT Social Stream

Latest CORT News From Around the Web

Below are the latest news stories about Corcept Therapeutics Inc that investors may wish to consider to help them evaluate CORT as an investment opportunity.

The Daily Biotech Pulse: Sanofi, GSK Begin Phase 1/2 Coronavirus Vaccine Study, Fulgent Strikes COVID-19 Testing Deal, New Data From Novavax

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Acutus Medical Inc (NASDAQ: AFIB ) Akouos Inc (NASDAQ: AKUS ) Avid Bioservices Inc (NASDAQ: CDMO ) ( reacted to strong quarterly results) BioLife Solutions Inc (NASDAQ: BLFS ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Edwards Lifesciences Corp (NYSE: EW ) Evogene Ltd (NASDAQ: EVGN ) Fortress Biotech (NASDAQ: FBIO ) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) (priced its 5.27-million-share common stock offering at $33 per share) Inspire Medical Systems Inc (NYSE: INSP ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Silk Road Medical Inc (NASDAQ: SILK ) Shockwave Medical Inc (NASDAQ: SWAV ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Twist Bioscience Corp ...

Benzinga | September 3, 2020

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q2 2020 Results - Earnings Call Transcript

Corcept Therapeutics, Inc. (CORT) Q1 2020 Earnings Conference Call August 04, 2020 5:00 PM ET Company Participants Charlie Robb – Chief Financial Officer Joseph Belanoff – Chief Executive Officer Conference Call Participants Chris Howerton – Jefferies Matt Kaplan – Ladenburg Thalmann Swayampakula Ramakanth – H.C. Wainwright Alan Leong – BioWatch...

SA Transcripts on Seeking Alpha | August 5, 2020

Corcept completes enrollment in mid-stage study of relacorilant in ovarian cancer

Corcept Therapeutics ([[CORT]] -0.2%) has completed enrollment of 177 metastatic ovarian cancer patients in a Phase 2 clinical trial assessing the combination of relacorilant and Bristol Myers Squibb's Abraxane (nab-paclitaxel) in patients who have failed to respond to platinum-based chemo.The primary endpoint is progression-free survival ((PFS)) at month 12. The...

Seeking Alpha | July 23, 2020

Corcept Therapeutics Completes Enrollment in Controlled, Phase 2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Ovarian Cancer

MENLO PARK, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced the completion of enrollment in its controlled, Phase 2 trial of relacorilant combined with nab-paclitaxel (Abraxane®) in patients with metastatic, platinum-resistant ovarian cancer. “We achieved this milestone thanks in part to the hard work and enthusiasm of our clinical investigators,” said Andreas Grauer, MD, Corcept’s Chief Medical Officer. “Data from our open-label, Phase 1/2 trial were very promising.1 We expect to have results from this larger, controlled trial in the first half of ne...

Yahoo | July 23, 2020

New GuruFocus Feature: Warren Buffett's Baskets

GuruFocus users can now assign stocks into one of several baskets Continue reading...

Yahoo | July 21, 2020

Read More 'CORT' Stories Here

CORT Price Returns

1-mo -1.17%
3-mo 9.42%
6-mo 35.31%
1-year 27.09%
3-year -3.32%
5-year 355.90%
YTD 46.94%
2019 -9.43%
2018 -26.02%
2017 148.76%
2016 45.78%
2015 66.00%

Continue Researching CORT

Here are a few links from around the web to help you further your research on Corcept Therapeutics Inc's stock as an investment opportunity:

Corcept Therapeutics Inc (CORT) Stock Price | Nasdaq
Corcept Therapeutics Inc (CORT) Stock Quote, History and News - Yahoo Finance
Corcept Therapeutics Inc (CORT) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.698 seconds.